Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
212M
-
Number of holders
-
199
-
Total 13F shares, excl. options
-
81.5M
-
Shares change
-
+4.48M
-
Total reported value, excl. options
-
$771M
-
Value change
-
+$42.8M
-
Put/Call ratio
-
0.83
-
Number of buys
-
77
-
Number of sells
-
-88
-
Price
-
$9.45
Significant Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q3 2020
245 filings reported holding SGMO - SANGAMO THERAPEUTICS, INC - Common Stock as of Q3 2020.
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) has 199 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 81.5M shares
of 212M outstanding shares and own 38.45% of the company stock.
Largest 10 shareholders include BlackRock Inc. (9.89M shares), VANGUARD GROUP INC (8.13M shares), WASATCH ADVISORS INC (7.11M shares), STATE STREET CORP (7.03M shares), Bellevue Group AG (3.85M shares), CREDIT SUISSE AG/ (3.05M shares), DIMENSIONAL FUND ADVISORS LP (2.29M shares), GOLDMAN SACHS GROUP INC (1.84M shares), TWO SIGMA INVESTMENTS, LP (1.78M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.76M shares).
This table shows the top 199 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.